EOFlow Officially Launches iOS Version of the EOPatch App ‘Narsha’
EOFlow Announces Record Revenue for First Quarter 2022; Revenue of 949 Million KRW which is 137% of Last Year’s Annual Revenue
EOFlow Has its First Clinical Study on EOPatch Published in Diabetes & Metabolism Journal
EOFlow to Supply KRW48.8bn Worth of EOPatch to Gulf Drug of UAE
EOFlow Celebrates its 10th Anniversary… Commits to Move Forward with a Goal Toward Becoming a “World’s Leading Medical Device Company”
EOFlow Makes a Significant Investment in EOPump Manufacturing Capacity
EOFlow Officially Launches EOPatch’s Smartphone Application ‘Narsha’
EOFlow Signs Mutual Equity Investment Agreement with UXN for Future Competitiveness
[Medical Observer] New Insulin and Insulin Delivery Devices the Paradigm Shift
[Medical Observer] EOFlow develops innovative medical device for diabetes
[SK Securities] Sales expected to increase in 2022
[MoneyToday] CEO interview on Pharmeo
[Hankyung BIO Insight] EOFlow plans to discover and develop various non-insulin drugs to expand on its wearable drug delivery business
EOFlow establishes a wearable pharmaceutical subsidiary 'Pharmeo Inc.' to expand on its wearable drug delivery business